ADVERTISEMENT
Lupin’s Troubles In U.S. Run Deep
Lupin’s API facility at Tarapur, Maharashtra is its fifth unit to face action from the U.S. FDA.
15 Jan 2020, 11:07 AM IST
Five plants of Lupin Ltd. have come under the U.S. drug regulator’s scanner over the last one year as the nation’s sixth-largest drugmaker failed to resolve quality issues amid intense competition and pricing pressure in its largest market.The company’s unit at Tarapur, Maharashtra is the latest to face action by the U.S. Food and Drug Administration, which classified the active pharmaceutical ingredient facility as “official action ...
I’m already a Subscriber Sign In
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Full Access to
NDTV Profit App
Exclusives
Premium Stories
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Minimal Ad
Experience
Members-Only
Rewards
Still Not convinced ? Know More
Get live Stock market updates, Business news, Today’s latest news, Trending stories, and Videos on NDTV Profit.
ADVERTISEMENT